The protease activity of the hepatitis C virus (HCV) NS3 protein has been investigated using transient expression methods in mammalian cells, as well as in vitro transcription/translation systems. We confirmed that expression of the NS3-5 polyprotein in rabbit reticulocyte lysates results in efficient cis processing at the NS3/NS4 junction. However, processing at the other predicted sites of NS3-mediated cleavage varied markedly in efficiency, the site most susceptible being that between NS5A and NS5B. Time-course analysis of the proteolytic processing of the HCV non-structural precursor showed that the cis cleavage between NS3 and NS4 occurred extremely rapidly. However, efficient cleavage at this position was dependent on the prior removal of the NS2 protein. Furthermore, the presence of uncleaved NS2 sequences on the enzyme severely impeded NS3-mediated proteolysis at downstream sites in the polyprotein. This suggests therefore that efficient cleavage at the NS2/NS3 junction is a pivotal event in HCV replication. During the course of this study a proteolytically inactive mutant of NS3 was characterized carrying a previously unreported amino acid substitution near the proposed active site of the enzyme. Molecular modelling suggested that the amino acid present at this position may influence the conformation of the active site of the enzyme. Recently a number of reports have described a second protease activity, located in the NS2/NS3 region, which is responsible for cleavage at the NS2/NS3 junction. We have identified an isolate of HCV, obtained from a U.K. patient, which has a virtually inactive NS2/NS3 protease. The possible implications of this observation are discussed.
Introduction
Hepatitis C virus (HCV) is the major aetiologic agent of parenterally transmitted non-A non-B hepatitis (NANBH) accounting for over 90 % of all cases of chronic NANBH and 25% of sporadic acute viral hepatitis Kuo et al., 1989; Alter et al., 1989) . This equates to 100000 to 300000 new cases per annum in the United States alone (Davis et al., 1990a; Weiner e t al., 1991 ). An extremely high rate of chronicity (Alter, 1989) linked to the high incidence of cirrhosis (Dienstag & Alter, 1986) has implicated chronic HCV infection with the development of hepatocellular carcinoma (Saito et al., 1990; Bukh et al., 1993) . Consequently chronic infection with HCV is emerging as a major healthcare problem throughout the world.
Several potential therapeutic agents have been used in various pilot studies against chronic NANBH (Pappas et aI., 1984; Stokes et at., 1987; Di Bisceglie et al., 1992; Kakumu et al., 1993) with little long-term effect. At the present time the only effective means of therapy is the use of interferon-7 over a long period of time. Many studies have shown (see Di Bisceglie & Hoofnagle, 1991 ) that prolonged therapy with interferon-~ leads to a decrease in liver cell dysfunction and amelioration of disease. However, the same studies have indicated that a large proportion (> 50%) of the patients who respond to interferon subsequently relapse into chronic disease when it is withdrawn (Davis et al., 1990b; Lindsay et al., 1990) . Furthermore, interferon-~ therapy is also associated with significant side-effects (Renault & Hoofnagle, 1989) . Consequently there is a great need for development of novel chemo-or immunotherapeutic approaches to the treatment of HCV-induced disease.
The viral agent responsible was initially characterized by Choo et al. (1989) as being a positive-strand RNA virus with a genome approximately 9500 bases in length. Since then a considerable amount of data have been accumulated on the basic molecular virology and replicative strategy of the virus.
The viral genome contains a single translational reading frame which potentially codes for a single large polyprotein (e.g. Kato et al., 1990; Choo et al., 1991; Takamizawa et al., 1991) ; this is nascently processed by a combination of viral and host cell proteases into mature viral proteins. Analysis of primary amino acid sequences and hydrophobicity profiles has indicated that the genomic organization of HCV closely resembles those of the Flavi-and Pestivirus genera (Miller & Purcell, 1990) and HCV is now considered to be a third distinct genus within the flavivirus family.
Genomic organization is such that the coding sequences for the structural proteins are located at the 5' end of the genome downstream of a long untranslated region which possesses an internal ribosomal entry site (TsukiyamaKohara et al., 1992; Kettinen et al., 1993; Wang et al., 1993) . Initiation of translation firstly results in the synthesis of nucleocapsid (C) and two putative envelope glycoproteins (El and E2), which are released from the nascent polyprotein by host proteases (Hijikata et al., 1991) . The remainder of the polyprotein is assumed to consist of the non-structural proteins necessary for viral replication. While functional roles for most of the proteins are still to be elucidated, sequence analysis indicates that the putative NS5 protein contains sequence motifs characteristic of RNA-dependent RNA polymerases (Takamizawa et al., 1991) . Similar amino acid analysis of the putative HCV NS3 protein shows conservation of residues His-1083, Asp-l107 and Ser-1165 among all HCV strains so far sequenced. The nature and position of these residues resembles the catalytic triad of chymotrypsin-like serine proteases. Furthermore, site-directed mutagenesis experiments (e.g. Chambers et al., 1990; Wiskerchen & Collett, 1991; Cahour et al., 1992) have shown that the NS3 protein plays a major role in polyprotein processing. The carboxy-terminal portion of HCV NS3 contains motifs characteristic of nucleoside triphosphate binding helicase domains (Gorbalenya et al., 1989; Miller & Purcell, 1990) , which are also found in the flavi-and pestiviruses (see Grakoui et al., 1993b for references), and a number of studies with various expression systems have reported either protease (Bartenschlager et al., 1993; Grakoui et al., 1993a, b; Hijikata et al., 1993; Tomei et al., 1993) or helicase (Suzich et al., 1993) activity in NS3. This apparent bifunctional role of the HCV NS3 protein means that it represents an extremely attractive target for antiviral therapy.
In this paper we investigate, using in vitro coupled transcription/translation systems, the proteolytic activity of an isolate of HCV derived from a U.K. patient. We show that there is a marked difference in the relative susceptibility of various cleavage sites to NS3 processing. Our data also enable us to identify an amino acid which is located near the active site of the enzyme and is implicated in proteolytic activity. We also show, using an in vitro system, that there is a requirement for the proteolytic removal of NS2 residues from the amino terminus of the molecule to activate the NS3 protease. Surprisingly, the U.K. isolate of HCV seems to be extremely inefficient in this process.
Methods
Plasmid constructs. All plasmids described in this study were constructed in Bluescript 1X KS transcription vectors (Stratagene) unless otherwise stated and HCV numbering refers to the genomic sequence of Kato et al. (1990) . Clones used for reconstructing the HCV non-structural coding region are shown in Fig. 1 (a) and were mainly generated from a U.K. patient with a chronic HCV infection by polymerase chain reaction (PCR) amplification with specific primers derived from sequence alignments of known HCV isolates (B. Rodgers and others, unpublished). However, most of SC957 is derived from a standard HCV cDNA library, in bacteriophage 2, which was identified by oligonucleotide hybridization. This clone extends from a naturally occurring PstI site at nucleotide 5535 through to the 3' untranslated region at nucleotide 9392. Complete details on construction of this clone will be published elsewhere (E. M. Amphlett and others; details available on request). The largest clone used in this study, ANS2-NS5, was constructed by ligation of several smaller clones (Fig. 1 a) . KS717 was initially constructed by ligation of smaller clones through common restriction sites and extends from nucleotide 2778 to 4241 with an artificial amino-terminal methionine for translation initiation. In order to facilitate manipulation, KS717 was modified by introduction of an oligonucleotide linker coding for a novel NheI site Clones were identified by screening recombinant cDNA libraries from donor serum obtained from a U.K. patient with a chronic HCV infection. Overlapping clones were ligated through naturally occurring restriction sites after introduction of an artificial Bsml site in clone pDX189 by site-directed mutagenesis. The reconstruction of SC957 will be published elsewhere (E. M. Amphlett and others). Clones G1007 and A1027 contain naturally occurring HCV sequence from glycine-1007 and alanine-1027 through to the translation termination codon. Both clones were derived from ANS2-NS5 as described in Methods. (b) Alignment of clones used for studying NS2/NS3 protease activity compared to the minimal active element described by Hijikata et al. (1993) . The clone from an Italian patient was generated by ligation of two specific PCR fragments through a common restriction site. KS717 and IT358 correspond to amino acids 817 to 1304 (U.K.) and 817 to 1208 (Italian) respectively. into the Nsil site at nucleotide 3096. Using a BamHl site in the 3' polylinker this NheI-BamHI fragment was subcloned downstream of a T7 promoter in the vector pGEMEX-1 (Promega). This clone was then extended by simultaneous ligation of a Sail Bsml (4149 to 4279) fragment from DX189 and a BsmI-BamHI (4280 to 5030) fragment from DX395. The resultant clone (3096 to 5030) was approximately 500 bases short of SC957. This segment was added by ligation of a SacI-Pstl fragment (4914 to 5535) generated by PCR ligation of clones DX395 and an overlapping clone DXI48. Finally SC957 was ligated onto this clone via the PstI site at 5535 to extend the coding sequence through to the 3' untranslated region.
The 5' truncated versions of this clone, G1007 and A1027, were generated by PCR-based mutagenesis from ANS2-NS5. Briefly ANS2-NS5 was used as template for PCR with either of the 5" primers 5' TTCATATGGCTAGCGGGCGTGAGATATTACTGG-GACCGGC 3' (G1007) or 5" TTCATATGGCTAGCGCGCCTA-TCACGGCCTACTCCCY (A1027) together with a common 3' primer, 5' GTGCCTTAGACATATACGCCCC 3', which annealed just downstream of a unique Avrll site (4111). The resultant PCR fragment was purified by agarose gel electrophoresis, cloned back as an NdeI Avrll fragment into ANS2-NS5 and verified by sequencing.
Site-directed mutagenesis of ANS2-NS5 was carried out to generate a consensus sequence as described in results. Initially a 3-8 kb NheI fragment from ANS2-NS5 was subcloned into a modified M13 vector and single-stranded DNA generated by standard procedures. This DNA was then used as template for site-directed mutagenesis with a T7 mutagenesis system (USB) and the following primers: (i) 5' CCT-GGGGGGCGGACACCGCGG 3' for T to A at 988; (ii) 5" CCC-CGGGGCCCGTTCCTTAACACCY for G to R at 1118; (iii) 5'GGAAACCACTATGCGGTCCCCGC 3' for V to M at 1205. Mutations were confirmed by sequencing and the 3-8 kb fragment was re-introduced into ANS~NS5.
For experiments to study the activity of the NS2/NS3 protease, KS717 (amino acids 817 to 1304) derived from the U.K. isolate was directly compared to a similar clone derived from an Italian isolate of HCV. This clone was originally derived by PCR with primers corresponding to this region and was subsequently modified (E. O'Sullivan and others, unpublished) to correspond to amino acids 817 to 1208.
In vitro transcription~translation. In all experiments, except the analysis of NS2/NS3 proteolysis, recombinant DNA clones were analysed using a Promega TNT-COUpled transcription/translation system. Typically DNA was purified using Wizard minipreps (Promega) and approximately 1 p.g was added directly to a T•'r reaction in the presence of [aSSlmethionine according to the manufacturer's instructions. Aliquots were removed at specific time-points and either analysed by radio-immunoprecipitation (see below) or dirctly by SDS-PAGE (Laemmli, 1970) and autoradiography.
Cleavage at the NS2/NS3 junction ( Fig. 5) was not efficient using the TNT system so conventional transcription/translation reactions were performed as previously described (Clarke & Sangar, 1988 ) using T7 RNA polymerase for transcription and translation in rabbit reticulocyte lysates. In these experiments the influence of membranes was also studied by the addition of canine pancreatic microsomal membranes (Promega) to the translation mixes for 2 h at 30 °C as described by the supplier.
Radio-immunoprecipitation analysis (RIPA).
Reticulocyte lysates were diluted with 2 vols of disruption buffer (2% SDS, 2% 2-mercaptoethanol, 10 % glycerol, 0-125 M-Tris-HC1 pH 6-8) and boiled for 2 rain. Samples were then diluted 20-fold in RIPA buffer (1% Triton X-100, 0-5 % sodium deoxycholate, 0.1% SDS in PBS) and 5 lal of undiluted antiserum added. After incubation overnight at 4 °C immune complexes were precipitated by adding 100 ~tl of 1% Pansorbin (Calbiochem) in RIPA buffer and incubating at room temperature for 30 min. Complexes were finally collected by centrifugation (10000 r.p.m., 10 s), washed twice in RIPA buffer and resuspended in disruption buffer before analysis by SDS-PAGE and autoradiography.
Results and Discussion

In vitro analysis of NS3 protease activity in reticulocyte tysates
Using a library of recombinant eDNA clones isolated from a U.K. patient with a chronic HCV infection, continuous sequences representing most of the nonstructural region of the genome were reconstructed (see Methods). These clones were inserted into T7 transcription vectors in order to analyse the proteolytic activity of proteins produced using in vitro transcription/ translation in rabbit reticulocyte lysates. Because of the reported involvement of the NS2 protein as a co-factor for NS3 protease activity in the flaviviruses our initial construct (ANS2-NS5) contained a portion of the predicted NS2 protein of HCV such that translation was initiated at amino acid 923 within NS2 (Fig. 1 a) and continued through to the end of the polyprotein. In vitro expression of ANS2-NS5. Purified DNA was added directly to a coupled transcription/translation system and the products were analysed by 10 % SDS-PAGE (Laemmli, 1970) . Lane 1 shows the protein products from ANS2 NS5 and lanes 2 and 3 show the products from two independent derivatives of ANS2-NS5 which were altered by site-directed mutagenesis to a consensus HCV sequence (see Methods). By analogy with similar reports of in vitro expression of HCV non-structural proteins from other isolates of the virus (Bartenschlager et al., 1993; Eckart et al., 1993; Grakoui et al., 1993a, b; Hijikata et al., 1993; Tomei et al., 1993) we expected to observe NS3-mediated proteolysis of the HCV polyprotein resulting in the appearance of the mature viral proteins NS3, NS4A, NS4B, NS5A and NS5B. Gel electrophoresis of the protein products from our isolate (Fig. 2, lane 1) showed an unexpected cleavage profile. Instead of the appearance of the mature viral proteins, the major products were a protein of 200K, representing the entire non-structural coding sequence present in the recombinant, and a band of approximately 80K. This product was larger than mature NS3, which other workers have shown to have a molecular mass of 70K, but RIPA analysis showed that it was precipitable with NS3-specific antisera (not shown). This property, together with the apparent molecular mass of the product, suggested that it was derived by cleavage at the NS3/NS4A junction but retained the additional extraneous sequences from NS2 at the amino terminus. This suggested that the cis cleavage between NS3 and NS4A had occurred but the cleavage between NS2 and NS3 had not. Furthermore, it was clear that apart from a possible processed product of 60K, the downstream NS3-mediated cleavages were extremely inefficient in this system. There are two possible explanations for the apparent inefficiency of the NS3 protease from this isolate. Firstly, it was possible that the protease itself was intrinsically less active due to sequence variation or, secondly, the presence of the extraneous NS2 sequences may have reduced the efficiency of the enzyme.
Amino acid sequence alignments were carried out across the region reported to be essential for NS3 activity to identify those amino acids in the U.K. isolate which were different from those conserved in all other published sequences. These amino acids were changed by sitedirected mutagenesis and re-introduced into the ANS2-NS5 background. Fig. 2 (lanes 2 and 3) shows that the properties of the resultant expressed proteins were essentially no different from the parental construct, suggesting that these amino acid variations were not responsible for the poor proteolytic activity.
The presence of extraneous NS2 sequences reduces the efficiency of NS3 protease activity in vitro
In order to assess the possible role of the extraneous NS2 sequences in inhibiting the NS3 protease activity, new Purified A1027 DNA was expressed in an in vitro transcription/translation system for 3 h. Aliquots were then analysed by RIPA using specific antisera. Lane 1, anti-peptide serum to NS3 (1043 to 1065); lane 2, serum raised against baculovirus-expressed NS5 with specificity for NS5A alone; lane 3, serum raised against baculovirus-expressed NS5A and NS5B; lanes 4 and 5, antisera raised against GST-NS3 fusion proteins produced in bacteria and purified by affinity chromatography; lane 6, control sample before precipitation.
constructs were prepared in which the NS2 sequences were removed. At that time the exact amino terminus of the NS3 protease had not been reported so two constructs (G1007 and A1027) were made starting either at amino acid Gly-1007 (chosen because it follows a dibasic amino acid sequence, a characteristic of flavivirus cleavage sites) or Ala-1027 (which was subsequently shown to be the authentic amino terminus of NS3). Fig.  3 shows a time-course of protein synthesis from these two clones compared to the ANS2-NS5 clone in a coupled transcription/translation system. In contrast to the extended clone, the two clones which initiate near or at the correct amino terminus of NS3 showed a much more complex pattern of proteins which corresponded in size to the predicted molecular mass of the mature viral nonstructural proteins. All three clones produced detectable amounts of the full-length precursor polypeptide but the two truncated clones showed more efficient cleavage of the polyprotein into discrete products. In this particular experiment the levels of the 80K ANS2-NS3 protein are lower than in Fig. 2 but the band can be seen to be larger than the putative NS3 band from G1007, which in turn is correspondingly slightly bigger than A1027 (as expected, because of its amino terminal extension). Fig. 3 also shows the parallel expression of a second clone which was isolated during the construction of A1027. Surprisingly, the processing profile of this clone (A1027Mut) was different from that of A1027 in that it showed efficient production of precursor polyprotein but, unlike A1027, did not process this into smaller products. Further investigation showed that the NS3 protease in this clone is active but processes more slowly than in A1027. The most likely reason for this difference in proteolytic activity between the two clones is a PCRinduced mutation arising during the truncation of the NS2 sequences from the ANS2-NS5 clone (see Methods). Analysis of the nucleotide sequence within the region which was amplified during the modification revealed a nucleotide substitution in A1027Mut which results in a Trp to Arg mutation at amino acid 1079. This mutation lies extremely close to the proposed active site His residue at 1083 and has recently been predicted to be part of a structurally conserved region based on crystallographic structure determination in related proteases (Pizzi et al., 1994) . Sequence alignments show that in all these structures the position homologous to Trp-1079 is occupied by a hydrophobic residue. The presence of the Arg at this position in the mutant not only introduces a hydrophilic amino acid but also a charge effect which may influence the role of either His-1083 or Asp-1107 in the catalytic function of the enzyme. Elucidation of the three-dimensional structure of the enzyme by X-ray crystallography may resolve this question.
Identification of the major processed products of HCV NS3 protease activity
It was confirmed that the apparent processing observed when clones A1027 and G1007 were expressed in vitro was due to the NS3 protease by parallel expression of clones in which the putative active site of NS3 had been altered by mutagenesis. The profile of the translation products from this construct was similar to that from A1027Mut (result not shown) except that processing of the polypeptide was completely abolished in the active site mutant, whereas some cleavage was observed with A1027Mut.
In order to confirm the identity of the in vitro cleavage products and to investigate the relative efficiency of cleavage at the predicted sites, clone A1027 was again expressed in an in vitro transcription/translation system and the products were analysed by immunoprecipitation with region-specific antisera. Antibodies directed against the NS3 region were either generated from synthetic peptides (Fig. 4, lane 1) or from bacterially expressed fusion proteins (lanes 4 and 5). In each case the antibodies precipitated the predicted 70K protein, believed to be the mature NS3 protein, with a small amount of the 200K precursor. Immunoprecipitation was also carried out using two antisera having specificity for either NS5A alone (lane 2) or both NS5A and NS5B (lane 3). The NS5A-specific serum precipitated proteins of 200K (precursor polypeptide), 56K (NS5A) and an unexpected protein of about 90K. Exactly the same immunoprecipitation profile was observed with the NS5A/NS5B-specific antibody with the additional appearance of a 65K protein (NS5B). Further work to confirm these results (not shown) showed that the 90K protein could be precipitated with an NS4B-specific antiserum but not with an NS5B-specific peptide antiserum. This reactivity and the size of this protein indicate that it represents NS4A-4B-5A from which NS3 and NS5B have been processed. Since a precursor protein corresponding to NS4A-4B-5A-5B is rarely seen this indicates that the NS3-mediated cleavage between NS5A and NS5B is the most efficient 'trans' cleavage observed in this system. Subsequent work has confirmed that when purified recombinant NS3 is added to an NS3-5 substrate in which the active site serine has been mutated the most efficient site for 'trans' cleavage is indeed NS5A/NS5B (E. D. A. D'Souza and others, unpublished) . In this case a major precursor protein representing NS3-NS4A-NS4B-NS5A is produced since the NS3/4A cleavage does not occur in trans.
Inactivity of NS2/NS3 protease from the U.K. virus
Recently a number of groups (Bartenschlager et al., 1993; Hijikata et al., 1993; Grakoui et al., 1993c) have shown that a second viral protease is responsible for proteolytic cleavage at the NS2/NS3 junction and that the activity of this enzyme lies in a region encompassing the carboxy terminus of NS2 and the amino terminus of NS3 overlapping the serine protease active site. This enzyme is reported to show characteristics of a zincdependent metalloproteinase and to have some dependence on the presence of microsomal membranes. The data shown in Fig. 3 indicate that the presence of extraneous sequences from NS2 have an inhibitory effect on the subsequent activity of the NS3 protease. Consequently it would seem that the activity of the NS2/NS3 protease is required to activate NS3. Hijikata et al. (1993) had shown that the region 898 to 1233 of NS2/NS3 was required for activity ( Fig. l b) but our clones lacked the amino-terminal portion of this sequence. We therefore extended our ANS2 constructs to contain the whole domain.
Initially, a KS717 clone expressing amino acids 817 to 1304 from the NS2/NS3 region (Fig. l b) was analysed by in vitro transcription/translation. Fig. 5 (lanes 4 and  5) shows that the major protein product generated from this clone, either in the presence or absence of membranes, was the 53K band expected for the uncleaved precursor with no evidence of cleavage to NS2 (23K) and NS3 (30K). (A band approximately 10K smaller than the major product is always observed in constructs initiating at this point which we believe to be spurious internal initiation.) In contrast, when clones encoding amino acids 817 to 1208 were constructed from an Italian isolate of the virus a different pattern was observed. In this case, although the precursor protein corresponding to unprocessed NS2/NS3 fusion protein (43K) was observed, two further protein products (23K and 20K) were also detected, their sizes corresponding to those of the predicted products of cleavage at the NS2/NS3 junction (lanes 2 and 3). The identities of the processed products were subsequently verified by RIPA with NS2-and NS3-specific antisera (not shown). The presence of microsomal membranes clearly enhanced the appearance of the processed products (lane 3), but was not essential for proteolysis.
Taken together these data indicate that although NS2/NS3 protease activity is present in the clone from the Italian isolate it appears to be absent from our clones of the U.K. virus. Detailed analysis of the sequence differences responsible for this apparent lack of activity were produced by T7 polymerase transcription of a U.K. and an Italian HCV clone covering the NS2/NS3 junction (see Fig. 1 b) . Transcripts were analysed by expression in rabbit reticulocyte lysates in either the presence ( + ) or absence ( -) of canine pancreatic microsomal membranes. Protein products were analysed by 10% SDS PAGE and autoradiography.
will be presented elsewhere (E. O'Sullivan and others) but the observation is worthy of discussion. The minimal domain required for the proteolytic activity at the NS2/NS3 junction resides in amino acid residues on either side of the cleavage site (Hijikata et al., 1993; Grakoui et al., 1993 c) . During the autocatalytic cleavage at this site, therefore, the enzyme effectively inactivates itself. However, it has recently been shown that the NS2/NS3 protease is able to process mutant substrates in trans using transient assays in mammalian cells (Grakoui et al., 1993c) . This implies that there must be levels of uncleaved NS2/NS3 fusion protein present in these cells which can mediate this process. It is interesting to note that the in vitro analysis shown here always shows a significant amount of uncleaved precursor. If viruses exist in which the release of fully active NS3 is defective then downstream processing events would also be impaired. Although it is conceivable that this defect may be partially compensated by higher levels of trans cleavage at the NS2/NS3 site by unprocessed, i.e. active NS2/NS3 protease, the replicative rate might be severely retarded and this could be an important factor in the development of persistent infection.
